Omeprazole
Proton Pump inhibitor, Antiviral Activity / H+,K+-ATPase inhibitor (IC50 = 5.8 μM). Clinically useful antisecretory and antiulcer agent.1 Potent inhibitor of CYP2C19 (Ki=3.1 mM).2 Inhibits swelling-dependent chloride channels.3 Facilitates oral bioavailability of bioactive peptides such as oxytocin by raising stomach pH.4 Displays broad spectrum antiviral activity.5 Enhances efficacy of remdesivir (10-fold).6
Biochemicals & reagents
73590-58-6
1) Satoh et al. (1989), Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats; J. Pharmacol. Exp. Ther., 248 806 2) Kuzin et al. (2018), Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine; Clin. Pharmacokinet, 57 729 3) Schmarda et al. (2000) The gastric H,K-ATPase blocker Iansoprazole is an inhibitor of chloride channels; Br. J. Pharmacol., 129 598 4) Maejima et al. (2020), Oral oxytocin delivery with proton pump inhibitor pretreatment decreases food intake; Peptides, 128 170312 5) Wantanabe et al. (2020), Selective Targeting of Virus Replication by Proton Pump Inhibitors; Sci. Rep., 10 4003 6) Bojkova et al. (2020), SARS-CoV2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles bioRxiv, epub ahead of print DOI: 10.1101/2020.04.03.024257
-20°C
TARGET: ATPase; Cytochrome/MDR -- DISEASE AREA: Infectious disease